| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2015 | US20150024034 Method and system for synthesizing nanocarrier based long acting drug delivery system for dexamethasone |
| 01/22/2015 | US20150024033 Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine |
| 01/22/2015 | US20150024032 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| 01/22/2015 | US20150024031 Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent |
| 01/22/2015 | US20150024028 Transdermal therapeutic system having improved long-term wearing comfort |
| 01/22/2015 | US20150024021 Method for treating a periodontal disease |
| 01/22/2015 | US20150024017 Compositions and methods for cell killing |
| 01/22/2015 | US20150024014 Treatment of disease with poly-n-acetylglucosamine nanofibers |
| 01/22/2015 | US20150024012 Article and methods for oral self-administration of nicotine |
| 01/22/2015 | US20150023993 Combination therapy using active immunotherapy |
| 01/22/2015 | US20150023990 Alkoxy substituted imidazoquinolines |
| 01/22/2015 | US20150023982 Methods of administering anti-tnfalpha antibodies |
| 01/22/2015 | US20150023975 PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| 01/22/2015 | US20150023973 Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of nup153 gene expression or nup153 activity as active ingredient |
| 01/22/2015 | US20150023965 Methods of treating urothelial carcinoma |
| 01/22/2015 | US20150023955 Treatment and Diagnosis of Melanoma |
| 01/22/2015 | US20150023954 Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
| 01/22/2015 | US20150023950 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System |
| 01/22/2015 | US20150023948 Formulation for treatment of irritable bowel disease |
| 01/22/2015 | US20150023941 Compositions Comprising Sugar-Cysteine Products |
| 01/22/2015 | US20150023940 Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme q10) |
| 01/22/2015 | US20150023937 Histone deacetylase (hdac) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy |
| 01/22/2015 | US20150023930 Aminoquinoline derivatives and uses thereof |
| 01/22/2015 | US20150023923 Methods for promoting neuronal development and/or health |
| 01/22/2015 | US20150023922 Methods for promoting neuronal development and/or health |
| 01/22/2015 | US20150023921 Hepatitis c antiviral compositions and methods |
| 01/22/2015 | US20150023920 Novel compositions and methods for preventing or treating cancer metastasis |
| 01/22/2015 | US20150023916 Antiviral drugs for treatment of arenavirus infection |
| 01/22/2015 | US20150023915 Treatment for melanoma |
| 01/22/2015 | US20150023914 Use of tellurium compounds for the treatment actinic keratosis |
| 01/22/2015 | US20150023913 Hepatitis C Virus Inhibitors |
| 01/22/2015 | US20150023912 Combinations of albumin-based drug delivery systems |
| 01/22/2015 | US20150023907 Reactivation of hiv-1 gene expression to treat persistent hiv infection |
| 01/22/2015 | US20150023905 Synthetic mechanical hemostatic composition, method of making and use thereof |
| 01/22/2015 | US20150023889 Fluoride-responsive riboswitchs, fluoride transporters, and methods of use |
| 01/22/2015 | US20150023888 Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine |
| 01/22/2015 | US20150023875 System for Targeted Delivery of Therapeutic Agents |
| 01/22/2015 | US20150023874 Folate receptor alpha binding ligands |
| 01/22/2015 | US20150023871 Compositions and methods for the diagnosis and treatment of tumor |
| 01/22/2015 | US20150023868 Hif inhibitors and use thereof |
| 01/22/2015 | US20150020824 Nicotine salt formulations for aerosol devices and methods thereof |
| 01/22/2015 | US20150020802 Low resistance aerosol exhalation filter |
| 01/22/2015 | DE19547958B4 Anthracyclin-Derivate Anthracycline derivatives |
| 01/22/2015 | DE102013011472A1 Vareniclin zur Behandlung nicht-stoffgebundener Abhängigkeiten Varenicline for treating non-substance-related dependencies |
| 01/22/2015 | CA2857397A1 Novel thickening composition comprising pregelatinized waxy potato starch or pregelatinized cassava starch |
| 01/21/2015 | EP2826784A1 Nucleoside phosphoramidate prodrugs |
| 01/21/2015 | EP2826780A1 Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition |
| 01/21/2015 | EP2826778A1 Azaindole derivatives as CFTR modulators |
| 01/21/2015 | EP2826776A1 Solid amorphous form of (R)-1(2,2-difluorobenzo(D)(1,3)dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)-cyclopropanecarboxamide |
| 01/21/2015 | EP2826774A1 Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives |
| 01/21/2015 | EP2826772A1 Intermediates for the synthesis of oxygen-substituted 3-heteroaroylamino-propionic acid derivatives |
| 01/21/2015 | EP2826771A2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction |
| 01/21/2015 | EP2826770A1 Acylguanidine compounds with antiviral activity |
| 01/21/2015 | EP2826769A1 Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof |
| 01/21/2015 | EP2826492A1 Drug delivery conjugate capable of controlled release, and use thereof |
| 01/21/2015 | EP2826491A1 Ophthalmic compositions containing a nitric oxide donor |
| 01/21/2015 | EP2826483A2 Mixture of substances comprising ribose and amino acids for treating sepsis, coagulopathies, bone healing disorders and/or bone bleeding |
| 01/21/2015 | EP2826482A1 Novel antitumor agent comprising combination of three agents |
| 01/21/2015 | EP2826481A1 Compositions containing riboflavin and sesamin-class compounds |
| 01/21/2015 | EP2826480A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 01/21/2015 | EP2826479A1 Ameliorating agent for chronic obstructive pulmonary disease |
| 01/21/2015 | EP2826478A1 Combinations comprising mglur modulators for the treatment of parkinson's disease |
| 01/21/2015 | EP2826477A1 Solid composition of amino carboxylate salt |
| 01/21/2015 | EP2826476A1 Calcium-free dialysis fluid |
| 01/21/2015 | EP2826475A1 Trans-clomiphene for treating diabetes in hypogonadal men |
| 01/21/2015 | EP2826474A1 Use of substituted diphenylamine compounds in preparing anti-tumour drugs |
| 01/21/2015 | EP2826473A1 Novel use of patchoulol |
| 01/21/2015 | EP2826472A2 Telomerase activating compounds and their use |
| 01/21/2015 | EP2826471A1 Use of hif alpha stabilizers for enhancing erythropoiesis |
| 01/21/2015 | EP2826470A1 Pharmaceutical combinations of pregabalin |
| 01/21/2015 | EP2826469A1 Encased tamper resistant controlled release dosage forms |
| 01/21/2015 | EP2826468A1 Encased tamper resistant controlled release dosage forms |
| 01/21/2015 | EP2826467A1 Encased tamper resistant controlled release dosage forms |
| 01/21/2015 | EP2826466A1 Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate |
| 01/21/2015 | EP2826465A1 Orally disintegrating tablet formulations of donepezil |
| 01/21/2015 | EP2826464A1 Sustained release solid dosage preparations |
| 01/21/2015 | EP2826371A2 Methods and compositions for inhibiting integrins using tellurium-containing compounds |
| 01/21/2015 | EP2825989A2 Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| 01/21/2015 | EP2825693A1 Methods and materials for treating cancer |
| 01/21/2015 | EP2825558A2 Combination therapy for the treatment of ovarian cancer |
| 01/21/2015 | EP2825542A1 Liver x receptor modulators |
| 01/21/2015 | EP2825541A1 Liver x receptor modulators |
| 01/21/2015 | EP2825540A1 Substituted imidazopyridazines |
| 01/21/2015 | EP2825539A1 Amorphous form of linagliptin and process for preparation thereof |
| 01/21/2015 | EP2825538A1 Positive allosteric modulators of mglur2 |
| 01/21/2015 | EP2825537A1 Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf |
| 01/21/2015 | EP2825528A1 Substituted pyrrolidine-2-carboxamides |
| 01/21/2015 | EP2825525A1 New polymorphic form of a long-acting beta-2 adrenoceptor agonist |
| 01/21/2015 | EP2825523A1 Novel sulfonate-based trimebutine salts |
| 01/21/2015 | EP2825518A1 Ultraviolet absorber |
| 01/21/2015 | EP2825261A1 Polypeptides and their use |
| 01/21/2015 | EP2825205A1 Polymeric conjugates of c1-inhibitors |
| 01/21/2015 | EP2825187A1 Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders |
| 01/21/2015 | EP2825184A1 Compositions and methods for treatment of pain |
| 01/21/2015 | EP2825178A1 Glycomimetics to inhibit pathogen-host interactions |
| 01/21/2015 | EP2825177A1 Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
| 01/21/2015 | EP2825176A1 Broad spectrum antibiotic arylomycin analogs |
| 01/21/2015 | EP2825175A1 Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| 01/21/2015 | EP2825174A1 Process for preparing sterile brinzolamide |
| 01/21/2015 | EP2825172A1 Paralytic shellfish poison |